NCT05582031View on ClinicalTrials.gov

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Anal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue SarcomaMalignant Pleural MesotheliomaSmall Cell Lung CarcinomaCastrate Resistant Prostate CancerNeuroendocrine Carcinoma of ProstateGastroenteropancreatic Neuroendocrine Neoplasm
Interventions
COMBINATION_PRODUCT

Regorafenib in combination with Tislelizumab

Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial

Sponsors

Collaborators (2)

Bayer
Novartis
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Translational Research in Oncology

OTHER